Veracyte Inc (VCYT)

Gross profit margin

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Gross profit (ttm) US$ in thousands 322,513 308,529 289,546 278,473 261,961 246,810 242,478 232,791 219,877 207,077 194,954 185,942 175,085 164,884 145,114 124,009 106,033 81,449 76,028 72,290
Revenue (ttm) US$ in thousands 479,129 463,393 445,764 425,331 399,579 375,473 361,051 343,149 328,633 311,175 296,536 283,575 268,353 250,594 219,514 186,714 157,465 123,064 117,483 112,677
Gross profit margin 67.31% 66.58% 64.95% 65.47% 65.56% 65.73% 67.16% 67.84% 66.91% 66.55% 65.74% 65.57% 65.24% 65.80% 66.11% 66.42% 67.34% 66.18% 64.71% 64.16%

June 30, 2025 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $322,513K ÷ $479,129K
= 67.31%

The gross profit margin of Veracyte Inc. has demonstrated a relatively stable and gradually improving trend over the analyzed period. Starting at approximately 64.16% as of September 30, 2020, the margin increased modestly throughout 2020 and 2021, reaching around 66.42% by September 30, 2021. This upward trajectory persisted into late 2021 and early 2022, with margins consistently remaining above 65.5%. The peak was observed on September 30, 2023, at approximately 67.84%, indicating an enhancement in the company's ability to generate gross profit relative to net sales.

Subsequent quarters exhibited slight fluctuations, with margins settling in the 65.45% to 67.31% range. Notably, there was a minor decline after the September 2023 peak, with the March 2024 figure at approximately 65.73%. The latest data from June and September 2024 show a modest decrease to around 65.56% and 65.47%, respectively. Future projections for 2025 indicate a potential slight rebound, with margins anticipated to return to the high 66% range, reaching approximately 67.31% by June 2025.

Overall, Veracyte Inc.’s gross profit margin reflects a consistent trend of maintaining healthy profitability levels, demonstrating effective cost management and pricing strategies within its operations. The margins have exhibited resilience and a capacity for incremental growth, with brief periods of fluctuation that do not significantly alter the overarching positive trajectory.